[go: up one dir, main page]

WO2022177409A1 - Composition pharmaceutique contenant des nanovésicules issues d'une souche de leuconostoc mesenteroides en tant que principe actif pour la prévention ou le traitement du cancer - Google Patents

Composition pharmaceutique contenant des nanovésicules issues d'une souche de leuconostoc mesenteroides en tant que principe actif pour la prévention ou le traitement du cancer Download PDF

Info

Publication number
WO2022177409A1
WO2022177409A1 PCT/KR2022/002598 KR2022002598W WO2022177409A1 WO 2022177409 A1 WO2022177409 A1 WO 2022177409A1 KR 2022002598 W KR2022002598 W KR 2022002598W WO 2022177409 A1 WO2022177409 A1 WO 2022177409A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
strain
composition
active ingredient
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/002598
Other languages
English (en)
Korean (ko)
Inventor
진화섭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liscure Biosciences Co Ltd
Original Assignee
Liscure Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220022360A external-priority patent/KR20220120498A/ko
Application filed by Liscure Biosciences Co Ltd filed Critical Liscure Biosciences Co Ltd
Publication of WO2022177409A1 publication Critical patent/WO2022177409A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention is leuconostoc mesenteroides (leuconostoc mesenteroides) strain, specifically, leuconostoc mesenteroides LB-LM1 (leuconostoc mesenteroides LB-LM1, accession number KCCM12701P) prevention of cancer comprising a strain-derived nanovesicles as an active ingredient , to a composition for improvement or treatment.
  • leuconostoc mesenteroides leuconostoc mesenteroides
  • LB-LM1 leuconostoc mesenteroides LB-LM1, accession number KCCM12701P
  • prevention of cancer comprising a strain-derived nanovesicles as an active ingredient , to a composition for improvement or treatment.
  • Cancer has the highest mortality rate worldwide and is the second most common cause of death in Western societies after cardiovascular disease.
  • the consumption of high-fat diets has become common due to the westernization of diets, and the incidence of colorectal cancer, breast cancer, and prostate cancer continues to increase due to the rapid increase in environmental pollutants and the increase in alcohol consumption.
  • Lung cancer is increasing due to an increase in the number of cancer cells and air pollution.
  • lactic acid bacteria are widely distributed in the oral cavity, intestine, vagina, feces, and fermented foods such as kimchi of humans and animals, and are closely related to the health of humans and animals. Lactobacillus has various health-promoting effects such as bowel action, suppression of harmful bacteria, immune regulation, lowering blood cholesterol, and anti-cancer.
  • prokaryotic cells such as bacteria and eukaryotic cells, which are host cells such as humans, secrete vesicles out of the cell, and the secreted endoplasmic reticulum performs various functions.
  • the extracellular vesicles secreted from bacteria contain endotoxin (lipopolysaccharide; LPS) and bacteria-derived proteins and genes.
  • endotoxin lipopolysaccharide; LPS
  • extracellular vesicles have been found in various secretions, feces, or tissue washing fluids of humans or animals, and the extracellular vesicles present in tissues are known to reflect the state of the tissue secreting the ER, and it is used to diagnose and diagnose diseases and It has been reported that it can be used for treatment.
  • Korean Patent Application Laid-Open No. 10-2005-0041808 discloses the anticancer activity of Leukonostok citrium strain
  • Korean Patent Publication No. 10-2019-0105522 discloses Lactobacillus genus bacterium-derived nanovesicles and their use.
  • specific experimental examples or examples confirming that the composition containing the leukonostok mecenteroides strain-derived nanovesicles are effective in the prevention or treatment of cancer has not been described.
  • another object of the present invention is to provide a food composition or a food additive composition for the prevention or improvement of cancer comprising a Leukonostok mecenteroides strain-derived nano-ER as an active ingredient.
  • another object of the present invention is to provide a feed composition or a feed additive composition for preventing or improving cancer of livestock comprising a Leukonostok mecenteroides strain-derived nano-ER as an active ingredient.
  • the present inventors identify and isolate the Leuconostoc mesenteroides LB-LM1 strain deposited at the Korea Microbial Conservation Center (Leuconostoc mesenteroides LB-LM1), isolate the nano-ER, and a composition comprising it as an active ingredient
  • Leuconostoc mesenteroides LB-LM1 strain deposited at the Korea Microbial Conservation Center (Leuconostoc mesenteroides LB-LM1)
  • isolate the nano-ER isolate the nano-ER
  • a composition comprising it as an active ingredient
  • a pharmaceutical composition for preventing or treating cancer comprising a leukonostok mecenteroides strain-derived nano-ER as an active ingredient.
  • the present invention provides a food composition or food additive composition for the prevention or improvement of cancer comprising a Leukonostok mecenteroides strain-derived nano-ER as an active ingredient.
  • the present invention provides a feed composition or feed additive composition for preventing or improving cancer of livestock comprising the Leukonostok mecenteroides strain-derived nano-ER as an active ingredient.
  • FIG. 1 is a view showing a graph measuring the cell growth rate (cell viability assay) after treating the Leukonostok mecenteroides strain-derived nano-ER in the lung cancer A549 cell line according to an embodiment of the present invention.
  • Figure 2 is a diagram showing a graph measuring the cell growth rate (cell viability assay) after treating the Leukonostok mecenteroides strain-derived nano-ER to the pancreatic cancer AsPC-1 cell line according to an embodiment of the present invention.
  • FIG. 3 is a view showing a graph measuring the cell growth rate (cell viability assay) after treating the leukonostok mecenteroides strain-derived nano-ER in the colon cancer HCT116 cell line according to an embodiment of the present invention.
  • Figure 4 is a diagram showing a graph measuring the cell growth rate (cell viability assay) after treating the leukonostok mecenteroides strain-derived nano-ER to the bladder cancer T24 cell line according to an embodiment of the present invention.
  • TNF- ⁇ expression in monocytes TNF-1
  • leukonostok mecenteroides strain-derived nanovesicles according to an embodiment of the present invention.
  • the Leuconostoc mesenteroides strain of the present invention may be a Leuconostoc mesenteroides LB-LM1 (Leuconostoc mesenteroides, LB-LM1, accession number KCCM12701P) strain, but is not limited thereto.
  • LB-LM1 Leuconostoc mesenteroides, LB-LM1, accession number KCCM12701P
  • Leuconostoc mesenteroides strain of the present invention is LB-LM1 (Leuconostoc mesenteroides, LB-LM1, Accession No. KCCM12701P)
  • the composition comprising the strain-derived nano-ER as an active ingredient has a preventive or therapeutic effect on cancer, and a pharmaceutical composition can be used as
  • the Leuconostoc mesenteroides LB-LM1 (Leuconostoc mesenteroides, LB-LM1) is a lactic acid bacteria strain.
  • the leukonostok mecenteroides LB-LM1 is a probiotic, and has a general intestinal effect and immune enhancing effect of lactic acid bacteria.
  • the leukonostok mecenteroides LB-LM1 is characterized in that it has a nucleic acid sequence of SEQ ID NO: 1 (SEQ ID NO: 1).
  • 'probiotics' is understood to mean 'living microorganisms that have a beneficial effect on the health of the host by improving the intestinal microbial environment of the host in the gastrointestinal tract of animals including humans'.
  • Probiotics are living microorganisms with probiotic activity, and when fed to humans or animals in the form of single or complex strains, in the form of dried cells or fermentation products, it can have a beneficial effect on the intestinal flora of the host.
  • the cancers include colorectal cancer, bladder cancer, breast cancer, black tumor, thyroid cancer, parathyroid cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, stomach cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, double gallbladder cancer, oral cancer, colon cancer, perianal cancer, liver cancer , may be any one cancer selected from the group consisting of lung cancer and blood cancer, but is not limited thereto.
  • the nanovesicles refer to structures made of nano-sized membranes secreted by various bacteria.
  • the nanovesicles are derived from the Leukonostok mecenteroides strain and may have an average diameter of 1 to 1000 nm, preferably 10 to 500 nm, but is not limited thereto.
  • the nanovesicles may be isolated from the Leukonostok mecenteroides strain by a natural or artificial method, and any method commonly used in the art may be used without limitation in the artificial method.
  • a commercially available exosome isolation kit eg, EXO-BB, ExoQuick®-ULTRA, ExoQuick®-TC, CapturemTM Exosome Isolation Kit, Total Exosome Isolation Kit, ExoTrapTM Exosome Isolation Spin Column Kit, Exo2DTM, etc.
  • a solution Separation according to the difference in specific gravity between resistant components eg, centrifugation
  • separation according to size eg, ultrafiltration or vacuum filter
  • separation based on affinity for a specific substrate eg, affinity chromatography
  • composition comprising the endoplasmic reticulum derived from the Leukonostok mecenteroides LB-LM1 strain according to the present invention may be administered orally or parenterally.
  • parenteral administration intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration and rectal administration, etc. may be administered, preferably by intravenous injection. can be administered, but is not limited thereto.
  • a suitable dosage of the composition may be variously prescribed according to factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity of the patient.
  • the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes an excipient, bog Release, sweetener, binder, coating agent, swelling agent, lubricant, lubricant or flavoring agent and the like can be used.
  • the pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
  • the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • suitable binders, lubricants, disintegrants and color-developing agents may also be included in the mixture.
  • suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate. ate, sodium acetate, sodium chloride, and the like.
  • Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like.
  • acceptable pharmaceutical carriers which are sterile and biocompatible, include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed.
  • diluents such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.
  • Leuconostoc mesenteroides LB-LM1 Leuconostoc mesenteroides, LB-LM1, Accession No. KCCM12701P
  • strain-derived composition comprising the nano-ER as an active ingredient of the present invention can be used as a food composition for preventing or improving cancer.
  • the food composition may be in the form of a health functional food.
  • Health functional food means food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act (Article 3, No. 1), and “functionality” means It refers to obtaining useful effects for health purposes such as regulating nutrients or physiological effects on the structure and function of the human body (Article 2).
  • the food composition may additionally contain food additives, and the suitability as a "food additive" is determined according to the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. and criteria.
  • Food Additives Codex for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as depigmentation, licorice extract, crystalline cellulose, and guar gum, L- Mixed preparations such as sodium glutamate preparation, noodle-added alkali preparation, preservative preparation, and tar color preparation can be mentioned.
  • chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid
  • natural additives such as depigmentation, licorice extract, crystalline cellulose, and guar gum
  • L- Mixed preparations such as sodium glutamate preparation, noodle-added alkali preparation, preservative preparation, and tar color preparation can be mentioned.
  • Foods containing the active ingredient of the present invention include bread, rice cakes, dried fruits, candies, chocolates, chewing gum, confectionery products such as jams, ice cream products, ice cream products, ice cream products such as ice cream powder milk, low-fat milk, lactose-decomposed milk, Processed milk, goat milk, fermented milk, buttermilk, concentrated milk, milk cream, butter oil, natural cheese, processed cheese, milk powder, milk products such as whey Processed meat products, processed eggs, meat products such as hamburgers Fish cakes, ham, Fish and meat products such as sausage and bacon processed fish and meat products Ramen, dried noodles, raw noodles, fried noodles, luxurious dried noodles, improved soft noodles, frozen noodles, pasta, etc.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may include a carbonation agent used in carbonated beverages, and the like.
  • the composition of the present invention may include fruit for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination.
  • the beverage composition including the active ingredient of the present invention is not particularly limited in other ingredients, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
  • natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.); disaccharides, (eg maltose, sucrose, etc.); and conventional sugars such as polysaccharides (eg, dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents taumatine, stevia extract (eg rebaudioside A, glycyrrhizin, etc.)
  • synthetic flavoring agents sacharin, aspartame, etc.
  • composition comprising the leuconostoc mesenteroides LB-LM1 (Leuconostoc mesenteroides, LB-LM1, accession number KCCM12701P) strain-derived nano-ER as an active ingredient of the present invention can be used as a feed composition for preventing or improving livestock cancer.
  • LB-LM1 Leuconostoc mesenteroides, LB-LM1, accession number KCCM12701P
  • strain-derived nano-ER as an active ingredient of the present invention can be used as a feed composition for preventing or improving livestock cancer.
  • the composition When the composition is prepared as a feed additive, the composition may be 20 to 90% highly concentrated or may be prepared in powder or granular form.
  • the feed additives include organic acids such as citric acid, humic acid, adipic acid, lactic acid, and malic acid, or phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, rosemary Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, any one or more of natural antioxidants such as phytic acid may be further included.
  • the composition When prepared as a feed, the composition may be formulated in the form of a conventional feed, and may include common feed ingredients together.
  • the feed and feed additives include grains such as milled or crushed wheat, oats, barley, corn and rice; plant protein feeds, such as feeds based on rape, soybean, and sunflower; animal protein feeds such as blood meal, meat meal, bone meal and fish meal; Sugar and dairy products, for example, may further include dry ingredients made of various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
  • the feed additive may be administered to the animal alone or in combination with other feed additives in an edible carrier.
  • the feed additive can be easily administered to the animal as a top dressing, directly mixing them with animal feed, or in an oral formulation separate from the feed.
  • a pharmaceutically acceptable edible carrier as well known in the art to prepare an immediate release or sustained release formulation.
  • Such edible carriers may be solid or liquid, for example cornstarch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol.
  • the feed additive may be a tablet, capsule, powder, troche or sugar-containing tablet or top dressing in microdispersed form.
  • the feed additive may be in the form of a gelatin soft capsule, or a syrup or suspension, emulsion, or solution.
  • the feed and feed additives may contain adjuvants, for example, preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, and the like.
  • the feed additive may be used by being added to animal feed by immersion, spraying, or mixing.
  • the feed or feed additive of the present invention can be applied to a number of animal diets including mammals, poultry and fish.
  • Pigs, cows, horses, sheep, rabbits, goats, rodents and experimental rodents as the mammals, as well as rats, hamsters, and guinea pigs, can be used for pets (eg, dogs, cats), etc., and chickens as the poultry, It can also be used for turkey, duck, geese, pheasant, and quail, and the like, and may be used for carp, crucian carp and trout as the fish, but is not limited thereto.
  • the present inventors isolated lactic acid bacteria from kimchi.
  • BLAST Basic Local Alignment Search Tool
  • SEQ ID NO: 1 The microorganism of the present invention having the nucleic acid sequence of SEQ ID NO: 1 was named Leukonostok mecenteroides LB-LM1, and was deposited at the Korea Microorganism Conservation Center on April 24, 2020 (Accession No. KCCM12701P).
  • LB-LM1 strain 0.1% of the Leukonostok mecenteroides LB-LM1 strain was inoculated into 30 ml of a vegetable broth and cultured at 37° C. for 18 hours stationary. After incubation, centrifuged at 3,500 rpm for 10 minutes, the culture solution was stored separately for nano-vesicle separation, and the cells were washed 3 times with PBS (phosphate buffered saline) solution to remove the remaining medium components and used for the experiment.
  • PBS phosphate buffered saline
  • the culture solution obtained after culturing the strain and 1M NaCl solution containing 16% PEG 6000 were mixed in the same amount and reacted at 4° C. for 15 hours. Thereafter, the reacted solution was centrifuged at 10,000 g, 4° C. for 20 minutes to obtain a nano-endoplasmic reticulum pellet.
  • the obtained nano-endoplasmic reticulum pellet was resuspended in 0.5M NaCl solution containing 5% PEG6000 and washed, followed by centrifugation at 11,000 rpm at 4°C for 20 minutes. After that, the supernatant was discarded and the pellet was resuspended in 1X PBS to finally separate the leukonostok mecenteroides-derived nanovesicles.
  • the present invention is lung cancer cell line (A549), pancreatic cancer (AsPC-1), bladder cancer (T24), colon cancer (HCT116) cells after culturing cells treated with Leukonostok mecenteroides LB-LM1 strain-derived nano-ER cells
  • the growth rate was measured through crystal violet staining, and the absorbance of the cancer cells treated with the particles derived from the empty medium was checked for the anticancer activity based on the 100% growth rate.
  • each cancer cell was plated with 1x10 4 cells in a 96-well plate, and then cultured for 24 hours in a cell incubator at 5% CO 2 , 37°C. Thereafter, the particles from the empty medium and the isolated nano-vesicles, or strains were treated for 24 hours.
  • cancer cell death was significantly reduced compared to the group treated with particles derived from the common medium and the group treated with the strain. increase was confirmed. In particular, it showed a very high cell growth inhibition rate at 50% in the lung cancer cell line A549 cell line, 63% in the pancreatic cancer cell line AsPC-1 cell line, and 43% in the colon cancer cell line HCT116 cell line. In addition, it was confirmed that cancer cell death was increased to a very high level when the composition according to the present invention was treated at 60% in the T24 cell line, which is a bladder cancer cell line. In light of the above results, it was confirmed that the leukonostok mecenteroides strain-derived nanovesicles could exhibit anticancer activity by effectively inhibiting the cell growth of cancer cells.
  • the increase in inflammatory cytokines in macrophages is known to induce anticancer efficacy.
  • Real-time polymerase chain reaction to determine the expression level of inflammatory cytokine genes according to the treatment of the leukonostok mecenteroides strain-derived nanovesicles. (qPCR) was performed.
  • Monocytes were prepared after incubation at 37°C and 5% CO2 condition using RPMI-1640 medium supplemented with penicillin/streptomycin, 10% FBS, and 2-mercaptoethanol. Monocytes (THP-1) were plated with 2x10 6 cells in a 6 well plate, and phorbol 12-myristate 13-acetate (PMA) was added to differentiate them into macrophages for 48 hours.
  • PMA phorbol 12-myristate 13-acetate

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pour la prévention, l'atténuation ou le traitement du cancer, la composition contenant, en tant que principe actif, des nanovésicules issues d'une souche de Leuconostoc mesenteroides, plus particulièrement une souche de Leuconostoc mesenteroides LB-LM1 (numéro d'enregistrement : KCCM12701P). Les nanovésicules issues de la souche de Leuconostoc mesenteroides selon la présente invention augmentent la mort des cellules cancéreuses et les substances inflammatoires (TNF-alpha) dans les macrophages dans divers carcinomes, et peuvent ainsi être efficacement utilisées en tant que composition pour traiter ou soulager le cancer chez l'homme ou l'animal.
PCT/KR2022/002598 2021-02-22 2022-02-22 Composition pharmaceutique contenant des nanovésicules issues d'une souche de leuconostoc mesenteroides en tant que principe actif pour la prévention ou le traitement du cancer Ceased WO2022177409A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2021-0023436 2021-02-22
KR20210023436 2021-02-22
KR1020220022360A KR20220120498A (ko) 2021-02-22 2022-02-21 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR10-2022-0022360 2022-02-21

Publications (1)

Publication Number Publication Date
WO2022177409A1 true WO2022177409A1 (fr) 2022-08-25

Family

ID=82930815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/002598 Ceased WO2022177409A1 (fr) 2021-02-22 2022-02-22 Composition pharmaceutique contenant des nanovésicules issues d'une souche de leuconostoc mesenteroides en tant que principe actif pour la prévention ou le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2022177409A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100013184A (ko) * 2008-07-30 2010-02-09 한국식품연구원 항암활성이 있는 로이코노스톡 메센테로이데스 6-2 균주 및상기 균주를 포함하는 김치
KR20140098708A (ko) * 2013-01-31 2014-08-08 부산대학교 산학협력단 신규한 스타터 균주 및 이를 이용한 김치를 포함하는 기능성 발효식품의 제조방법
KR20170128247A (ko) * 2015-01-23 2017-11-22 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
KR20190143337A (ko) * 2018-06-19 2019-12-30 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
KR20200128501A (ko) * 2018-01-31 2020-11-13 서울대학교산학협력단 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
KR20210112980A (ko) * 2020-03-05 2021-09-15 주식회사 리스큐어바이오사이언시스 류코노스톡 속 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100013184A (ko) * 2008-07-30 2010-02-09 한국식품연구원 항암활성이 있는 로이코노스톡 메센테로이데스 6-2 균주 및상기 균주를 포함하는 김치
KR20140098708A (ko) * 2013-01-31 2014-08-08 부산대학교 산학협력단 신규한 스타터 균주 및 이를 이용한 김치를 포함하는 기능성 발효식품의 제조방법
KR20170128247A (ko) * 2015-01-23 2017-11-22 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
KR20200128501A (ko) * 2018-01-31 2020-11-13 서울대학교산학협력단 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
KR20190143337A (ko) * 2018-06-19 2019-12-30 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
KR20210112980A (ko) * 2020-03-05 2021-09-15 주식회사 리스큐어바이오사이언시스 류코노스톡 속 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물

Similar Documents

Publication Publication Date Title
WO2020122484A1 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer, comprenant weissella cibaria wikim28 en tant que substance active
KR101995328B1 (ko) 항암 활성을 갖는 락토바실러스 퍼멘텀 WiKim0102 및 이를 유효성분으로 포함하는 조성물
WO2023033624A1 (fr) Composition pharmaceutique pour la prevention ou le traitement du cancer comprenant la souche weissella paramesenteroides wikim0137 comme principe actif
KR102511221B1 (ko) 류코노스톡 속 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
AU2021214534B2 (en) Pharmaceutical composition for preventing or treating cancer, comprising Weissella cibaria WIKIM28 as active ingredient
WO2021177600A1 (fr) Composition pharmaceutique comprenant une souche du genre leuconostoc utilisée comme principe actif pour la prévention ou le traitement du cancer
US20220062355A1 (en) Pharmaceutical composition comprising lactobacillus sakei wikim30 as active ingredient for prevention or treatment of cancer
WO2022145901A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant des nanovésicules dérivées d'une souche de lactobacillus fermentum en tant que principe actif
KR20220094154A (ko) 락토바실러스 퍼멘텀 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022177409A1 (fr) Composition pharmaceutique contenant des nanovésicules issues d'une souche de leuconostoc mesenteroides en tant que principe actif pour la prévention ou le traitement du cancer
WO2022177412A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant en tant que principe actif des nanovésicules issues d'une souche de weissella cibaria
WO2022145900A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant en tant que principe actif des nanovésicules issues d'une souche de weissella cibaria
KR102390775B1 (ko) 류코노스톡 슈도메센테로이데스 WiKim0138 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
KR102789369B1 (ko) 와이셀라 시바리아 lbml2 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022145902A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement du cancer, comprenant des nanovésicules dérivées d'une souche de lactobacillus sakei en tant qu'ingrédient actif
KR20220120498A (ko) 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102339314B1 (ko) 와이셀라 시바리아 wikim28을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20220120503A (ko) 와이셀라 시바리아 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022177411A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant une souche de weissella cibaria lbml2 en tant que principe actif
RU2824372C1 (ru) Фармацевтическая композиция для предотвращения или лечения рака, содержащая weissella cibaria wikim28 в качестве активного ингредиента
CA3166609C (fr) Composition pharmaceutique pour la prevention ou le traitement du cancer, comprenant weissella cibaria wikim28 en tant que principe actif
KR20220094155A (ko) 락토바실러스 사케아이 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20220094153A (ko) 와이셀라 시바리아 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022197124A1 (fr) Composition pour la prévention ou le traitement du cancer au moyen de l'induction de la maturation de cellules dendritiques immatures
WO2022169337A1 (fr) Composition pharmaceutique comprenant une souche de leuconostoc citreum utilisée en tant que principe actif pour la prévention ou le traitement de lésions intestinales

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22756607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22756607

Country of ref document: EP

Kind code of ref document: A1